BALTIMORE, MD March 24, 2020 – PathSensors Inc, a Baltimore biotechnology company, announced today that they are developing a CANARY ™ biosensor to detect the Novel SARS Coronavirus (SARS-CoV-2), the causal agent for the coronavirus disease COVID–19. The biosensor will be available for research purposes in May 2020 and validation data on the new SARS-CoV-2 product will be available June 2020.
CANARY ™ technology provides a unique opportunity to reduce the impending public health impact of COVID-19 with rapid results and high specificity. The initial application for this PathSensors product will be for testing of environmental swabs and air monitoring in sensitive spaces such as hospitals, offices, food services, etc. PathSensors will continue to advance the assay’s capabilities as the novel virus is further characterized. As the SARS-CoV-2 biosensor is commercialized, PathSensors expects new uses to emerge, such as rapid specimen screening.